NeuroPace, Inc. reported $99M of revenue over the trailing twelve months, +17% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $99M (to Q2 2026). Net income: −$19M, trailing twelve months to Q2 2026. Free cash flow: −$12M, trailing twelve months to Q2 2026. Operating margin: −16%, trailing twelve months to Q2 2026.

NPCENeuroPace, Inc.

Healthcare

$12.37+16% 1Y

$12.37

$9.4052 weeks$19.29

NPCE as reported

NeuroPace, Inc. reported $99M of revenue over the trailing twelve months, +17% on the year before. 10 reported series are charted on this page, each one as filed.

$99M

Revenue, trailing twelve months · to Q2 2026 · +17% against the twelve months before

Net income: −$19M
Net income · −26% year on year · trailing twelve months to Q2 2026
Free cash flow: −$12M
Free cash flow · −29% year on year · trailing twelve months to Q2 2026
Operating margin: −16%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NPCE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$99M	+17%	Q2 2026
Net income	−$19M	−26%	Q2 2026
EPS	−$0.57	−31%	Q2 2026
Gross margin	80%	n/a	Q2 2026
Operating margin	−16%	n/a	Q2 2026
Net margin	−20%	n/a	Q2 2026
ROE	−138%	n/a	Q2 2026
ROA	−21%	n/a	Q2 2026
ROIC	−77%	n/a	Q2 2026
Free cash flow	−$12M	−29%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.